Physician profile
Jenna Danielle Andre
NPI 1467073122
$3,619.44
in general payments reported to CMS, 2019-2025
14 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $608 · 2023: $786 · 2024: $1,690 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,084.22 | 2022-2025 | Clareon, Hydrus Microstent, Centurion |
| Abbvie INC. | $946.13 | 2022-2025 | Durysta, Lumigan, Vuity |
| Sight Sciences, INC. | $749.16 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $209.49 | 2022-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Dompe US, INC. | $133.33 | 2024 | Oxervate |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Alimera Sciences, INC. | $125.00 | 2022 | |
| Axogen | $53.02 | 2025 | |
| Mallinckrodt Hospital Products INC. | $51.28 | 2024 | Acthar |
| Bausch & Lomb Americas INC. | $45.06 | 2023-2025 | Vyzulta, Lotemax Sm |
| Amgen INC. | $32.82 | 2024 | Uplizna |
| Alexion Pharmaceuticals, INC. | $24.33 | 2023 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $22.98 | 2024 | Syfovre |
| Zimmer Biomet Holdings, INC. | $17.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Andre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.